Article Details
Retrieved on: 2021-05-27 20:26:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
ST101, a first-in-class peptide antagonist of C/EBPβ is currently in a Phase 1/2 ... Sapience Therapeutics, Inc., is a privately held, clinical stage biotechnology ... With platform-based discovery of peptide therapeutics that disrupt ...
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here